Gyre Therapeutics
GYRE
65 hedge funds and large institutions have $75.7M invested in Gyre Therapeutics in 2021 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 9 increasing their positions, 31 reducing their positions, and 16 closing their positions.
5,982% more call options, than puts
Call options by funds: $5.11M | Put options by funds: $84K
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
6% less funds holding
Funds holding: 69 → 65 (-4)
5.95% less ownership
Funds ownership: 64.56% → 58.61% (-6%)
13% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 16
53% less capital inflows, than outflows
Capital inflows: $6.6M | Capital outflows: $14M
71% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OrbiMed
New York
|
+$2.6M |
| 2 |
Pura Vida Investments
New York
|
+$1.63M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$464K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$287K |
| 5 |
J. Goldman & Co
New York
|
+$267K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Stonepine Capital Management
Bend,
Oregon
|
-$1.94M |
| 2 |
Renaissance Technologies
New York
|
-$1.79M |
| 3 |
Verition Fund Management
Greenwich,
Connecticut
|
-$1.68M |
| 4 |
Acuta Capital Partners
Redwood City,
California
|
-$1.4M |
| 5 |
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$1.14M |
GYRE Hedge Fund Activity: Q3 2021 in Review
65 of the 5,733 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q3 2021, worth a combined $75.7M — down 14% from $87.7M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of GYRE and 14 opened new positions — a net loss of 2 holders — while 31 trimmed existing stakes and 9 added.
The largest buyer was OrbiMed, adding an estimated $2.6M. The largest seller was Stonepine Capital Management, cutting an estimated $1.94M.
- 65 institutional investors held Gyre Therapeutics (GYRE) as of Q3 2021, down from 69 in Q2 2021.
- Funds reported $75.7M of Gyre Therapeutics stock for Q3 2021, down 14% quarter-over-quarter.
- 14 funds opened new Gyre Therapeutics positions in Q3 2021 and 16 closed out, a net change of -2 holders.
- The largest Gyre Therapeutics buyer in Q3 2021 was OrbiMed, an estimated $2.6M added.
- The largest Gyre Therapeutics seller in Q3 2021 was Stonepine Capital Management, an estimated $1.94M sold.
Based on aggregated 13F filings for Q3 2021.